Literature DB >> 30416046

Doses of radiation to the pericardium, instead of heart, are significant for survival in patients with non-small cell lung cancer.

Jianxin Xue1, Chengbo Han2, Andrew Jackson3, Chen Hu4, Huan Yao5, Weili Wang6, James Hayman7, Weijun Chen8, Jianyue Jin6, Gregory P Kalemkerian9, Martha Matuzsak7, Struti Jolly7, Feng-Ming Spring Kong10.   

Abstract

BACKGROUND AND
PURPOSE: Higher cardiac dose was associated with worse overall survival in the RTOG0617 study. Pericardial effusion (PCE) is a common cardiac complication of thoracic radiation therapy (RT). We investigated whether doses of radiation to the heart and pericardium are associated with PCE and overall survival in patients treated with thoracic radiation for non-small cell lung cancer (NSCLC).
MATERIALS AND METHODS: A total of 94 patients with medically inoperable/unresectable NSCLC treated with definitive RT in prospective studies were reviewed for this secondary analysis. Heart and pericardium were contoured consistently according to the RTOG1106 Atlas, with the great vessels and thymus of the upper mediastinal structures included in the upper part of pericardium, only heart chambers included in the heart structure. Clinical factors and dose-volume parameters associated with PCE or survival were identified via Cox proportional hazards modeling. The risk of PCE and death were mapped using DVH atlases.
RESULTS: Median follow-up for surviving patients was 58 months. The overall rate of PCE was 40.4%. On multivariable analysis, dosimetric factors of heart and pericardium were significantly associated with the risk of PCE. Pericardial V30 and V55 were significantly correlated with overall survival, but presence of PCE and heart dosimetric factors were not.
CONCLUSION: PCE was associated with both heart and pericardial doses. The significance of pericardial dosimetric parameters, but not heart chamber parameters, on survival suggests the potential significance of radiation damage to the cranial region of pericardium.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Heart dose; NSCLC; Pericardial dose; Pericardial effusion

Mesh:

Year:  2018        PMID: 30416046      PMCID: PMC6445767          DOI: 10.1016/j.radonc.2018.10.029

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  10 in total

Review 1.  Radiation-Associated Pericardial Disease.

Authors:  Natalie Szpakowski; Milind Y Desai
Journal:  Curr Cardiol Rep       Date:  2019-07-27       Impact factor: 2.931

Review 2.  Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: current clinical trials and prospective challenges.

Authors:  Hui Yang; Tao Jin; Mengqian Li; Jianxin Xue; Bo Lu
Journal:  Precis Clin Med       Date:  2019-03-13

3.  Using Auto-Segmentation to Reduce Contouring and Dose Inconsistency in Clinical Trials: The Simulated Impact on RTOG 0617.

Authors:  Maria Thor; Aditya Apte; Rabia Haq; Aditi Iyer; Eve LoCastro; Joseph O Deasy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-11-13       Impact factor: 7.038

4.  Dosimetric feasibility of stereotactic ablative radiotherapy in pulmonary vein isolation for atrial fibrillation using intensity-modulated proton therapy.

Authors:  Xue-Ying Ren; Peng-Kang He; Xian-Shu Gao; Zhi-Lei Zhao; Bo Zhao; Yun Bai; Si-Wei Liu; Kang Li; Shang-Bin Qin; Ming-Wei Ma; Jing Zhou; Yi Rong
Journal:  J Appl Clin Med Phys       Date:  2021-04-04       Impact factor: 2.102

5.  Probing thoracic dose patterns associated to pericardial effusion and mortality in patients treated with photons and protons for locally advanced non-small-cell lung cancer.

Authors:  Laura Cella; Serena Monti; Ting Xu; Raffaele Liuzzi; Arnaldo Stanzione; Marco Durante; Radhe Mohan; Zhongxing Liao; Giuseppe Palma
Journal:  Radiother Oncol       Date:  2021-05-09       Impact factor: 6.901

Review 6.  Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions.

Authors:  Kathryn Banfill; Meredith Giuliani; Marianne Aznar; Kevin Franks; Alan McWilliam; Matthias Schmitt; Fei Sun; Marie Catherine Vozenin; Corinne Faivre Finn
Journal:  J Thorac Oncol       Date:  2020-12-03       Impact factor: 15.609

7.  Using Novel Statistical Techniques to Accurately Determine the Predictive Dose Range in a Study of Overall Survival after Definitive Radiotherapy for Stage III Non-Small Cell Lung Cancer in Association with Heart Dose.

Authors:  Joshua R Niska; Jiuyun Hu; Jing Li; Michael G Herman; Cameron S Thorpe; Steven E Schild; Mirek Fatyga
Journal:  J Cancer Ther       Date:  2021-09-29

Review 8.  Role of Real-World Data in Assessing Cardiac Toxicity After Lung Cancer Radiotherapy.

Authors:  Azadeh Abravan; Gareth Price; Kathryn Banfill; Tom Marchant; Matthew Craddock; Joe Wood; Marianne C Aznar; Alan McWilliam; Marcel van Herk; Corinne Faivre-Finn
Journal:  Front Oncol       Date:  2022-07-19       Impact factor: 5.738

Review 9.  DNA damage response in vascular endothelial senescence: Implication for radiation-induced cardiovascular diseases.

Authors:  Masaki Nagane; Hironobu Yasui; Periannan Kuppusamy; Tadashi Yamashita; Osamu Inanami
Journal:  J Radiat Res       Date:  2021-07-10       Impact factor: 2.724

10.  Why aren't we getting consistent results for heart dose and mortality during thoracic radiotherapy?

Authors:  Jianxin Xue; You Lu; Feng-Ming Spring Kong
Journal:  Ann Transl Med       Date:  2020-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.